Protagonist Therapeutics (PTGX) to Release Earnings on Wednesday

Protagonist Therapeutics (NASDAQ:PTGX) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Protagonist Therapeutics to post earnings of $2.11 per share and revenue of $199.8120 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The firm had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. On average, analysts expect Protagonist Therapeutics to post $4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Protagonist Therapeutics Stock Up 0.9%

Shares of PTGX opened at $136.84 on Wednesday. The business’s 50 day moving average is $118.26 and its two-hundred day moving average is $102.21. Protagonist Therapeutics has a 52-week low of $50.49 and a 52-week high of $143.29. The firm has a market cap of $8.80 billion, a price-to-earnings ratio of -75.60 and a beta of 1.79.

Insider Activity

In related news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the completion of the sale, the chief executive officer owned 523,478 shares of the company’s stock, valued at $52,410,617.36. This represents a 12.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $922,880.50. This represents a 53.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 161,130 shares of company stock valued at $16,355,220. Company insiders own 5.19% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp lifted its holdings in shares of Protagonist Therapeutics by 18.5% in the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after purchasing an additional 500,924 shares during the last quarter. Wellington Management Group LLP grew its stake in Protagonist Therapeutics by 66.2% during the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after buying an additional 1,262,977 shares during the last quarter. Janus Henderson Group PLC grew its stake in Protagonist Therapeutics by 140.7% during the 4th quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock worth $231,355,000 after buying an additional 1,549,160 shares during the last quarter. Invesco Ltd. increased its position in Protagonist Therapeutics by 56.2% in the fourth quarter. Invesco Ltd. now owns 1,567,840 shares of the company’s stock worth $136,935,000 after buying an additional 564,134 shares during the period. Finally, Woodline Partners LP increased its position in Protagonist Therapeutics by 51.9% in the third quarter. Woodline Partners LP now owns 1,438,247 shares of the company’s stock worth $95,543,000 after buying an additional 491,363 shares during the period. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on PTGX. The Goldman Sachs Group restated a “neutral” rating and issued a $110.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. TD Cowen reissued a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, July 1st. Zacks Research raised shares of Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. Wolfe Research assumed coverage on shares of Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 target price on the stock. Finally, Truist Financial increased their price target on shares of Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $123.00.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.